Objective: Comorbidities such as DM accelerate the progression of NAFLD/NASH to AdvLD [compensated cirrhosis (CC)/decompensated cirrhosis (DCC)/liver transplant (LT)/hepatocellular carcinoma (HCC)]. This study examined the impact of DM on healthcare costs among NAFLD/NASH patients with AdvLD in the U.S.

Methods: Adult NAFLD/NASH patients identified from IBM Watson Health MarketScan claims database (2006-2016) were followed from initial NAFLD/NASH diagnosis to identify development of AdvLD (first diagnosis as index date), stratified by presence of DM (ICD codes/medications). Mean annual healthcare costs for each stage was obtained from per patient per month values (2016 USD). Results: Overall 468,017 NAFLD/NASH patients were identified with 24% having DM (mean age 51 years, 58% females, high comorbidity burden - 56% hypertension, 55% hyperlipidemia). Mean annual costs were higher (p<0.05) for DM vs. non-DM patients (Figure) among NAFLD/NASH, CC, and DCC patients.

Conclusions: Comorbid DM is associated with significantly higher (23-31%) healthcare costs in patients with NAFLD/NASH, CC, and DCC, which represents the majority clinical burden of NAFLD in the U.S. Novel treatment options are needed among NAFLD/NASH patients with DM to prevent progression and subsequent healthcare costs.


R. Wong: Advisory Panel; Self; Gilead Sciences, Inc. Consultant; Self; Gilead Sciences, Inc. Research Support; Self; Gilead Sciences, Inc. Speaker's Bureau; Self; Gilead Sciences, Inc. N. Kachru: Employee; Self; Gilead Sciences, Inc. Stock/Shareholder; Self; Gilead Sciences, Inc. D. Martinez: None. M. Moynihan: Employee; Self; IBM. A. Ozbay: Employee; Self; Gilead Sciences, Inc. Stock/Shareholder; Self; Gilead Sciences, Inc. S. Gordon: Consultant; Self; Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.